BreatheSuite
Upcoming SlideShare
Loading in...5
×
 

BreatheSuite

on

  • 352 views

 

Statistics

Views

Total Views
352
Views on SlideShare
351
Embed Views
1

Actions

Likes
0
Downloads
1
Comments
0

1 Embed 1

http://storify.com 1

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    BreatheSuite BreatheSuite Presentation Transcript

    • BreatheSuite A Medical Device in your pocket
    • Eric Larson, PhD Candidate, Electrical Engineering. Commercialized past patent to Belkin. Co-lead on BreatheSuite’s patents. Matt Jasper, MBA Candidate Founded 2 IP licensing businesses. Handles customer development. Mayank Goel, PhD Candidate, Computer Science. Founded home automation business. Co-lead on BreatheSuite’s patents. BreatheSuite Team
    • Shwetak Patel UW Professor in CSE & EE, MacArthur Genius Grant Recipient Jim Stout, MD UW Medicine, Spirometry 360 Creator, Primary Care Physician Margaret Rosenfeld, MD Seattle Children’s Hospital, Clinical Pulmonologist Rachael Tanner & Kathie Jordan, Coulter Foundation David Hammond, Regulatory Consultant Greg Free, GSEC Mentor Board of Advisors
    • Asthma COPD Cystic Fibrosis Chronic Respiratory Disease
    • World Health Organization World Asthma Foundation 1 out of every 7 people have a respiratory disease
    • Diagnosis: Spirometer measures volume and flow of air from the lungs
    • 90% of hospitals in developing nations do not have spirometers
    • Solution: BreatheSuite
    • From Any Phone
    • Everyone has access
    • BreatheSuite’s Impact Reduce hospitalizations Fewer deaths
    • Head To Head Evaluation
    • Head To Head Evaluation Test results identical International Conference on Ubiquitous Computing, 2012
    • Head To Head Evaluation Test results identical Doctor diagnosis identical International Conference on Ubiquitous Computing, 2012
    • Current Status
    • Current Status
    • Current Status
    • Current Status
    • Traction: In The News
    • Traction: Key Customers
    • Traction: Key Customers Global Health Non- Profits
    • Global Health Non-Profits Handles: Developing World Healthcare Needs: mHealth solutions
    • Global Health Market 1 Billion People 6 Billion Phones World Health Organization
    • Global Health Non-Profits
    • Traction: Key Customers Global Health Non- Profits
    • Traction: Key Customers PharmaceuticalsGlobal Health Non- Profits
    • Pharmaceuticals: Clinical Trials Market: 6000+ respiratory trials Cost: $1 B per drug Time: 15 years per drug
    • Go To Market Pharmaceuticals DevelopingWorld Secondary Markets
    • Business Model PharmaceuticalsGlobal Health Non- Profits Setup fee Per Trial, Per Patient fee Shared Distribution Channels Paid Use Model via Buyers
    • Competition Full Diagnosis Limited Diagnosis SoftwareHardware Spirometers Peak Flow Meters FEV1 Meters BreatheSuite
    • Financial Summary $- $10 $20 $30 $40 $50 $60 2013 2014 2015 Millions 2013 2014 2015 Revenue $7 $21 $41 Net Income $3 $10 $18 Break Even in Year 1 M M M M M M
    • Social Return On Investment
    • Social Return On Investment Fewer deaths from COPD and asthma a 10% reduction = 325,000 lives return of 65M – 1.3B dollars per year World Health Organization Burden of Obstructive Lung Disease World Asthma Foundation
    • Social Return On Investment Fewer hospitalizations a 10% reduction > 1M hospital stays return of 600M – 4B dollars per year World Health Organization Burden of Obstructive Lung Disease World Asthma Foundation
    • Social Return On Investment Every dollar spent = conservative: 2.6 dollars of impact more realistic: 8.6 dollars of impact
    • Offer Grant Funding: $800,000 with $100,000 committed Equity Funding: $3M-$5M Grant funding: commercialization & regulatory approval Equity Funding: Technology scaling & sales
    • Thank you Thanks to: Deb Wolf & the GSEC staff, Greg Free GSEC judges and volunteers BreatheSuite’s board of advisors The University of Washington BreatheSuite A Medical Device in your pocketwww.breathesuite.com info@breathesuite.com @breathesuite
    • BreatheSuite A Medical Device in your pocket
    • Appendix: How It Works Audio Vocal Tract Model Flow rate
    • Appendix: Side By Side Comparison Raw Audio: 5.2% Call In Service:6.4% ATS Range: 5-7%
    • Appendix: Leading Causes of Death World Health Organization
    • Appendix: Disability Adjusted Life Years Global Burden of Disease, 2007
    • Global Health Non-Profits
    • Appendix: Financials: Pharma Pharma Revenue Projections Pharma Cost Projections
    • Appendix: Financials: Dev World Dev World Cost Assumptions DevWorld Revenues have not been factored into our overall initial BreatheSuite revenue projections, as the Pharma Revenue is more than enough to cover both pharma and dev world costs. However, we are building out a paid use model with developing world global health partners that includes revenue that will both cover costs, provide healthy margins, and be affordable to those who need our technology the most.
    • Appendix: Income Statement & FCF
    • Appendix: Social Impact Summary Inputs Outputs Outcomes Impacts $8 M-$39 M $220M-$2.4 B $2 B-119 B $9 B-$365 B Drugs brought to market quicker Increased rates of smoking cessation Less hospitalization, self management of disease, better health More trials have integrated spirometry results Spirometry provides teaching moment for smokers Increased number of people performing spirometry Increased number of people performing spirometry Cost of application, cost of training in new trials Doctors, Education & Ad Campaigns, Application Services Time, Access to phone, Remote Care Workers, Doctors Time, Access to phone, Remote Care Workers, Doctors Pharmaceuticals Developing Respiratory Drugs Global Health Non-Profits Undiagnosed COPD patients Undiagnosed Asthma Patients Stakeholders Less hospitalization, self management of disease, better health Total Impact $40 B – $524 B $8 M-$39 M $220M-$2.4 B $20 B-119 B $20 B-$365 B
    • Appendix: Social Impact Summary Inputs Outputs Outcomes Impacts $8 M-$39 M $220M-$2.4 B $20 B-119 B $20 B-$365 B Drugs brought to market quicker Increased rates of smoking cessation Less hospitalization, self management of disease, better health More trials have integrated spirometry results Spirometry provides teaching moment for smokers Increased number of people performing spirometry Increased number of people performing spirometry Cost of application, cost of training in new trials Doctors, Education & Ad Campaigns, Application Services Time, Access to phone, Remote Care Workers, Doctors Time, Access to phone, Remote Care Workers, Doctors Pharmaceuticals Developing Respiratory Drugs Global Health Non-Profits Undiagnosed COPD patients Undiagnosed Asthma Patients Stakeholders Less hospitalization, self management of disease, better health Totals $40 B – $524 B $4.1B/yr $10.6B- $35B/yr